NEJM February 5,2026 Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

This clinical study investigates whether a novel drug combination can improve outcomes for patients facing HER2-positive metastatic breast cancer who have not yet received treatment. By comparing a pairing of trastuzumab deruxtecan and pertuzumab against the current standard medical care, researchers found that the new regimen significantly extended progression-free survival, reaching a median of over forty months. While the innovative therapy produced superior tumor response rates, it also carried a specific risk of interstitial lung disease that requires careful monitoring. Ultimately, the trial demonstrates that this treatment duo offers a more effective first-line defense than traditional chemotherapy-based options for managing advanced disease.